Professor of Medicine, University Mich Medical School
Oncology
Dr. Maha H. Hussain, MD
|
|
Give Review
Maha Hussain practices Oncology. He went to Wayne State University School of Medicine. Wayne State University School of Medicine has a rank of 63 in research and a 85 in primary care He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Fellow (FASCO)". Maha Hussain is a published doctor as well. He has 67 publications published. The latest was: Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. He accepts all Medicare patients.
Publications
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
- A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prost...
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase 3 metastatic castration resistant prostate Cancer trial.
- Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study.
- Molecular Pathways: Targeting ETS Gene Fusions in Cancer.
- Bladder Cancer: Bladder preservation-learning what we don't know.
- A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial Carcinoma.
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate Cancer.
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...
- Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial Carcinoma.
- Words of wisdom. Re: Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract Carcinoma.
- Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421.
- Intermittent Androgen Deprivation Therapy in Advanced Prostate Cancer.
- Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial Carcinoma.
- Evaluation of the Anti-Tumor Activity of Dacomitinib in Models of Human Bladder Cancer.
- Castration-Resistant Prostate Cancer: AUA Guideline.
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate Cancer (SWOG S0421): a randomised phase 3 trial.
- Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate Cancer.
- A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the Bladder.
- Non-castrate metastatic prostate Cancer: have the treatment options changed?
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers.
- Intermittent versus continuous androgen deprivation in prostate Cancer.
- Emerging therapies in metastatic castration-sensitive and castration-resistant prostate Cancer.
- Randomized clinical trial of a brief and extensive dyadic intervention for advanced Cancer patients and their family caregivers.
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
- The changing natural history of metastatic prostate Cancer.
- Integrin alpha(2)beta (1) (α (2)β (1)) promotes prostate Cancer skeletal metastasis.
- Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate Cancer.
- Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder Cancer: A multidisciplinary approach.
- Evolving therapeutic paradigms for advanced prostate Cancer.
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate Cancer treated with intermittent androgen ablation.
- Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the Bladder.
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate Cancer.
- Phase II open-label study of oral piritrexim in patients with advanced Carcinoma of the urothelium who have experienced failure with standard chemotherapy.
- Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate Cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and ...
- A prospective Analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinica...
- Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective.
- Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell Cancer of the bladder: a Southwest Oncology Group trial.
- Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate Cancer.
- SWOG-9510: evaluation of topotecan in hormone refractory prostate Cancer: a Southwest Oncology Group study.
- Southwest Oncology Group studies in hormone-refractory prostate Cancer.
- American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (cast...
- Bladder Cancer: narrowing the gap between evidence and practice.
- Innovations and challenges in prostate Cancer: summary statement for the 6th Cambridge Conference.
- Potential surrogate endpoints for prostate Cancer survival: analysis of a phase III randomized trial.
- Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate Cancer trial.
- Oral etoposide in the treatment of hormone-refractory prostate Cancer.
- Hormonal therapy for prostate Cancer: past, present and future.
- Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck Cancer (E1395): an intergroup trial of the Ea...
- Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patie...
- Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder Cancer cases: a Southwest Oncology Group Study.
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study.
- The rationale for adjuvant chemotherapy for high-risk prostate Cancer.
- A phase II trial of estramustine and etoposide in hormone refractory prostate Cancer: A Southwest Oncology Group trial (SWOG 9407).
- Phase II trial of bicalutamide in patients with advanced prostate Cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
- Evaluation of proState-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
- Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate Cancer previously treated with taxanes.
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate Cancer.
- Quality of life and pain in advanced stage prostate Cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone...
- A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell Carcinoma of the head and ...
- Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostat...
- A sequential treatment approach to myoinvasive urothelial Cancer: a phase II Southwest Oncology Group trial (S0219).
- Antiandrogen withdrawal in castrate-refractory prostate Cancer: a Southwest Oncology Group trial (SWOG 9426).
- Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial Carcinoma: results of a multicenter ...
- The patient with hormone-refractory prostate Cancer: determining who, when, and how to treat.
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- CoreSource
- First Health (Coventry Health Care) PPO
- Health Alliance
- Preferred PPO
- Choice Care PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- NGS CoreSource
- Paramount
- Principal Life
- Priority PPO
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FASCO)
Education
-
Wayne State University School of Medicine -
University of Baghdad College of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1245316199 | |
| NPPES Provider LastName | HUSSAIN | |
| NPPES Provider FirstName | MAHA | |
| NPPES Provider ZIPCode | 481095913 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 373.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1245316199 |
| Last Name Of The Provider | HUSSAIN |
| First Name Of The Provider | MAHA |
| View All |
Similar Doctors
|
|
Dr. Max S. Wicha, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Francis P. Worden, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Kathleen A. Cooney, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Douglas W. Blayney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Megan E. Caram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dean E. Brenner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Attaphol Pawarode, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Phillip L. Palmbos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick J. Hu, MD
This Doctor is OpenDoctor Recommended.
|